Revolution Medicines, Inc. 8-K

What Happened Revolution Medicines, Inc. announced on April 17, 2026 that it issued $500,000,000 aggregate principal amount of 0.50% Convertible Senior Notes due May 1, 2033. The Notes are senior, unsecured obligations issued under an indenture with U.S. Bank Trust Company, N.A. Interest accrues at 0.50% per year, paid semi‑annually beginning November 1, 2026. The company may settle conversions in cash, shares of common stock, or a combination, and the initial conversion rate is 5.0302 shares per $1,000 principal (initial conversion price ≈ $198.80 per share). An underwriting agreement with J.P. Morgan Securities, TD Securities (USA) and Guggenheim Securities was entered on April 14, 2026.

Key Details

• Amount: $500,000,000 aggregate principal of 0.50% Convertible Senior Notes due May 1, 2033.
• Coupon & payments: 0.50% annual interest, payable semi‑annually on May 1 and November 1 (first payment Nov 1, 2026).
• Conversion: Initial rate 5.0302 shares per $1,000 principal (≈ $198.80/share); conversions may be settled in cash, stock, or both; limited conversion rights before Feb 1, 2033 except upon specified events.
• Redemption & repurchase: Company may redeem on or after May 6, 2030 if stock trades above 130% of the conversion price under specified tests; holders may require repurchase upon certain “Fundamental Change” events.
• Underwriting & legal: Underwriters agreed to purchase the Notes (underwriting agreement filed); Latham & Watkins provided a legal opinion on validity.

Why It Matters This transaction raises $500M of new financing at a very low interest cost (0.50%), which reduces near‑term cash interest expense versus traditional debt. However, the Notes are convertible into common stock at an initial price of about $198.80, so if converted they would dilute existing shareholders. Conversion is limited until early 2033 except in certain events, meaning dilution may occur later or upon corporate events. The Notes are unsecured and structurally subordinated to any subsidiary liabilities, and redemption/repurchase features could affect the timing of potential dilution or cash outflows. Investors should note the new liability on the balance sheet, the low coupon, and the potential for future equity issuance if conversions occur.